Article thumbnail

Update on the rational use of tositumomab and iodine-131 tositumomab radioimmunotherapy for the treatment of non-Hodgkin’s lymphoma

By Michael J Burdick and Roger M Macklis


Targeted radioimmunotherapy in non-Hodgkin’s B-cell lymphoma (NHL) offers an efficacious therapy and minimal toxicity compared to conventional chemotherapy. Iodine 131 tositumomab (131I-TST) is a murine monoclonal antibody against the CD20 cell surface protein and is directly covalently conjugated to 131I, a radioactive β and γ emitter. While initially approved for use in relapsed, refractory, or transformed low grade B-cell NHL, investigational uses with promising results include autologous stem cell transplant, intermediate grade NHL, and the frontline management of indolent NHL. This review summarizes the 131I-TST literature on mechanism of action, treatment indications, treatment delivery, efficacy, investigational uses, and future prospects

Topics: Review
Publisher: Dove Medical Press
OAI identifier:
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles


  1. (2003). 131I-Anti CD20 radioimmunotherapy of relapsed or refractory nonHodgkins lymphoma: a phase II clinical trial of a nonmyeloablative dose regimen of chimeric rituximab radiolabeled in a hospital. Cancer Biother Radiopharm.
  2. (2005). 131I-tositumomab therapy as initial treatment for follicular lymphoma.
  3. 18F-FDG PET/CT for monitoring the response of lymphoma to radioimmunotherapy.
  4. 3-dimensional dosimetry in non-Hodgkin’s lymphoma patients treated with 131I-anti-B1 antibody: assessment of tumor dose-response.
  5. A phase I/II trial of iodine131-tositumomab (anti-CD20), etoposide, cyclophosphamide, and autologous stem cell transplantation for relapsed B-cell lymphomas.
  6. Abbreviated chemotherapy with fludarabine followed by tositumomab and iodine 131I tositumomab for untreated follicular lymphoma.
  7. Antibody specificity controls in vivo effector mechanisms of anti-CD20 reagents.
  8. Apoptosis of malignant human B cells by ligation of CD20 with monoclonal antibodies.
  9. Assessment of treatment-related myelodysplastic syndromes and acute myeloid leukemia in patients with non-Hodgkin lymphoma treated with tositumomab and iodine 131I tositumomab.
  10. (2005). Bexxar (Tositumomab and Iodine 131I Tositumomab): Prescribing Information.
  11. (2008). Cancer statistics,
  12. (2003). CD20-induced lymphoma cell death is independent of both caspases and its redistribution into triton X-100 insoluble membrane rafts. Cancer Res.
  13. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
  14. Cloning of the chromosome breakpoint of neoplastic B cells with the t(14;18) chromosome translocation.
  15. Commentary: let the tail wag the dog: the case for radioimmunotherapy of low-grade follicular lymphoma.
  16. Complement-mediated lysis by anti-CD20 mAb correlates with segregation into lipid rafts.
  17. (2007). Dose-attenuated radioimmunotherapy with tositumomab and iodine 131 tositumomab in patients with recurrent non-Hodgkin’s lymphoma (NHL) and extensive bone marrow involvement. Leuk Lymphoma.
  18. Efficacy and safety of tositumomab and iodine-131 tositumomab (Bexxar) in B-cell lymphoma, progressive after rituximab.
  19. Follow-up of relapsed B-cell lymphoma patients treated with iodine-131-labeled anti-CD20 antibody and autologous stem-cell rescue.
  20. High-dose [131I]tositumomab (anti-CD20) radioimmunotherapy and autologous hematopoietic stem-cell transplantation for adults 60 years old with relapsed or refractory B-cell lymphoma.
  21. High-dose chemoradioimmunotherapy with autologous stem cell support for relapsed mantle cell lymphoma.
  22. High-dose radioimmunotherapy versus conventional high-dose therapy and autologous hematopoietic stem cell transplantation for relapsed follicular non-Hodgkin lymphoma: a multivariable cohort analysis.
  23. High-grade transformation of chronic lymphocytic leukemia and low-grade non-Hodgkin’s lymphoma. Genotypic confirmation of clonal identity.
  24. IDEC-C2B8 (Rituximab) anti-CD20 antibody treatment in relapsed advanced-stage follicular lymphomas: results of a phase-II study of the German Low-Grade Lymphoma Study Group. Ann Hematol.
  25. (1997). IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin’s lymphoma.
  26. (1996). Iodine-131-anti-B1 radioimmunotherapy for B-cell lymphoma. J Clin Oncol.
  27. (2009). Maintenance or eradication of residual disease in indolent lymphoma: where do we stand? J Clin Oncol.
  28. Maintenance rituximab after cyclophosphamide, vincristine, and prednisone prolongs progressionfree survival in advanced indolent lymphoma: results of the randomized phase III ECOG1496 Study.
  29. Metabolic response of non-Hodgkin’s lymphoma to 131I-anti-B1 radioimmunotherapy: evaluation with FDG PET.
  30. Multicenter phase II clinical study of iodine-131-rituximab radioimmunotherapy in relapsed or refractory indolent non-Hodgkin’s lymphoma.
  31. Multicenter phase II study of iodine-131 tositumomab for chemotherapy-relapsed/refractory low-grade and transformed low-grade B-cell non-Hodgkin’s lymphomas.
  32. Overview of non-Hodgkin’s lymphoma: biology, staging, and treatment.
  33. Phase I trial of iodine-131 tositumomab with high-dose chemotherapy and autologous stem-cell transplantation for relapsed non-Hodgkin’s lymphoma.
  34. (2004). Phase II study of CVP followed by tositumomab and iodine 131I tositumomab (Bexxar therapeutic regimen) in patients with untreated follicular non-Hodgkin’s lymphoma (NHL). J Clin Oncol (Meeting Abstracts).
  35. Phase II trial of 131I-B1 (anti-CD20) antibody therapy with autologous stem cell transplantation for relapsed B cell lymphomas.
  36. Phase II trial of CHOP chemotherapy followed by tositumomab/iodine I-131 tositumomab for previously untreated follicular non-Hodgkin’s lymphoma: five-year follow-up of Southwest Oncology Group Protocol S9911.
  37. Pivotal study of iodine 131I tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin’s lymphomas.
  38. (2008). Radiation therapy with tositumomab (B1) anti-CD20 monoclonal antibody initiates extracellular signal-regulated kinase/mitogen-activated protein kinase-dependent cell death that overcomes resistance to apoptosis. Clin Cancer Res.
  39. Radioimmunotherapy of B-cell lymphoma with [131I]anti-B1 (anti-CD20) antibody.
  40. Radioimmunotherapy with iodine (131I) tositumomab for relapsed or refractory B-cell nonHodgkin lymphoma: updated results and long-term follow-up of the University of Michigan experience.
  41. (2001). Radioimmunotherapy with iodine-131 tositumomab in patients with low-grade non-Hodgkin’s B-cell lymphoma does not induce loss of acquired humoral immunity against common antigens. Clin Immunol.
  42. Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support.
  43. Re-treatment with I-131 tositumomab in patients with non-Hodgkin’s lymphoma who had previously responded to I-131 tositumomab.
  44. Revised response criteria for malignant lymphoma.
  45. Rituximab blocks binding of radiolabeled anti-CD20 antibodies (Ab) but not radiolabeled anti-CD45
  46. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.
  47. Subsequent therapy can be administered after tositumomab and iodine I-131 tositumomab for non-Hodgkin lymphoma.
  48. (2004). The radioisotope contributes significantly to the activity of radioimmunotherapy. Clin Cancer Res.
  49. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene.
  50. Tositumomab and iodine 131I tositumomab for recurrent indolent and transformed B-cell non-Hodgkin’s lymphoma.
  51. Tositumomab and iodine-131 tositumomab produces durable complete remissions in a subset of heavily pretreated patients with low-grade and transformed non-Hodgkin’s lymphomas.
  52. Type II (tositumomab) anti-CD20 monoclonal antibody out performs type I (rituximab-like) reagents in B-cell depletion regardless of complement activation.
  53. Users fear that lymphoma drugs will disappear.